AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04692792 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dai Dai flower drink
Description: consume 1 bottle (50 mL) per day for 8 weeks
Study NCT05321355 — intervention group
Intervention type: DEVICE
Intervention: Implantation of vagus nerve stimulation according to clinical indication
Description: no interventions, only observation
Study NCT04001179 — intervention group
Intervention type: OTHER
Intervention: Pulmonary embolism diagnosis by nuclear medicine imaging
Description: nuclear medicine imaging
Study NCT05101070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-531011
Description: Administered by intravenous infusion
Study NCT05101070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Administered by intravenous infusion
Study NCT04931641 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Galacto-oligosaccharides
Description: Prebiotic galacto-oligosaccharides (GOS)
Study NCT04931641 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Maltodextrin (placebo)
Study NCT04931641 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ferrous fumarate
Description: 50 mg iron as ferrous fumarate
Study NCT04931641 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Ferrous fumarate
Description: 50 mg iron as ferrous fumarate
Study NCT06213038 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: SKG0106
Description: SKG0106 is a recombinant adeno-associated virus (AAV) vector-based in vivo gene therapeutic product
Study NCT05336136 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Custom mask
Description: Custom mask based on 3D facial photograph for administration of non-invasive ventilation
Study NCT05325190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granisetron Transdermal Patch System
Description: Granisetron transdermal patch 3.1mg was given 48 hours before the first day of chemotherapy, Dexamethasone 12mg was taken orally on the first day of chemotherapy and dexamethasone 8mg was taken orally on the second and third days of chemotherapy,3.1mg granisetron transdermal patch was replaced on the 5th day of chemotherapy. Granisetron transdermal patch was removed and discarded on the 12th day of chemotherapy.
Study NCT05782361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tepotinib
Description: Tepotinib hydrochloride hydrate will be supplied as film coated tablets. The 250 mg oval, white-pink film-coated tablets contain the excipients mannitol, microcrystalline cellulose, crospovidone, magnesium stearate, colloidal silicon dioxide, and Opadry II pink. All formulations are intended for oral administration. Refer to pharmacy manual for formulation and strength information.
Study NCT05782361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab Solution for Infusion 100 mg/vial is a liquid drug product supplied as a clear to opalescent solution, essentially free of visible particles, in Type I glass vials and manufactured using the fully formulated drug substance with L-histidine as buffering agent, polysorbate 80 as surfactant, and sucrose as stabilizer/tonicity modifier.~Pembrolizumab Solution for Infusion can be further diluted with normal saline or 5% dextrose in the concentration range of 1 to 10 mg/mL in IV containers made of polyvinyl chloride (PVC) or non-PVC material.
Study NCT04913688 — intervention group
Intervention type: PROCEDURE
Intervention: bedside ultrasound performed group
Description: If deep vein thrombosis (DVT) is suspected among patients who visit the emergency department, an emergency physician performs bedside ultrasound of lower extremities to the patients agreed to participate in this study. The patients also are examined duplex ultrasound by radiologist.
Study NCT05076669 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stoma follow-up
Description: delivery and enhanced follow-up by the FSK HHN provided, in particular, by stomal therapy nurse consultants and patient-relation experts during in-person or remote appointments in addition to the routine care delivered and prescribed by the sites
Study NCT05076669 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard of care
Description: routine management of stoma
Study NCT05336136 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Current commercial mask
Description: Current commercial mask used for administration of non-invasive ventilation
Study NCT06481033 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Real Time fMRI Neurofeedback
Description: The proposed pilot study is designed to collect feasibility and acceptability data regarding the utility of real-time functional magnetic resonance imaging (rt-fMRI) feedback in reducing suicide-specific rumination in veterans. Fifteen veterans will receive 2 rt-fMRI neurofeedback sessions while attempting to alter connectivity in brain regions that play a role in rumination. Pre- and post-treatment assessments of suicide, disability, functional impairment, and quality of life will be collected.
Study NCT06643754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-3276
Description: Dose Escalation: SHR-3276 will be administered intravenously. 4 dose levels are preset.~Dose Expansion: 2 to 3 dose cohorts will be selected for dose expansion stage.~Indication Expansion: Indications will be selected to evaluate preliminary efficacy.
Study NCT05462353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2mg of ASC41
Description: ASC41 tablet administered orally once daily.
Study NCT05462353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4mg of ASC41 (2 tablets of 2 mg ASC41)
Description: ASC41 tablets administered orally once daily.
Study NCT05462353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets administered orally once daily.
Study NCT05462353 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets administered orally once daily.
Study NCT06274970 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced recovery protocols
Description: Aforementioned in the detailed description
Study NCT06274970 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Protocols
Description: Conventional protocols for non-ERASP group Eg: No preoperative vitamin D and calcium supplementation etc.
Study NCT05682144 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Plasmablasts (B cells)
Description: Autologous plasmablasts (B cells) engineered to express α-L-iduronidase (IDUA) using the Sleeping Beauty (SB) transposon system.
Study NCT06373289 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: higher oxygen saturation target using Nellcor pulse oximetry sensors
Description: The intervention will be a cross over exposure to the higher oxygen saturation target.
Study NCT06373289 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lower oxygen saturation target using Nellcor pulse oximetry sensors
Description: The intervention will be a cross over exposure to the lower oxygen saturation target.
Study NCT04958031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVL-871 1.0 mg
Description: CVL-871 1.0 mg, oral (tablet), once per day for 12 weeks (stepped up-titration of dose days 1-7)
Study NCT04958031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVL-871 3.0 mg
Description: CVL-871 3.0 mg QD oral (tablet), once per day for 12 weeks (stepped up-titration of dose days 1-21)
Study NCT04958031 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo QD, oral (tablet), once per day for 12 weeks
Study NCT04680026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HBI-3000
Description: Small molecule, multi-ion channel blocker
Study NCT04954794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab will be administered at 200 mg i.v. every 3 weeks plus a bevacizumab biosimilar at 15 mg/kg i.v. every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
Study NCT04954794 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: TACE
Description: TACE is performed by using drug-eluting beads or using microspheres combined with Lipiodol-pirarubicin emulsion per Investigator's decision. TACE treatment starts at day 0. Sintilimab plus a bevacizumab biosimilar will be initiated on day 14 after TACE.
Study NCT04680026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal saline
Study NCT06104176 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT in group
Description: All subjects will have 4 sessions of group CBT (one per week) during the first month following their inclusion, and then randomly assigned (ratio 1:1) to VRET group or individual CBT group. Subjects will undergo 4 additional sessions of VRET or individual CBT (one per week) during the second month.~VRET consists on 4 weekly sessions (one per week, for 1 month) of 60 to 90 minutes duration. Each session, consists in 20 to 30 minutes exposure with 10 minutes breaks (2 to 3 exposure per session). Four environments will be used: The home environment, the metro advertising environment , the party environment, and the supermarket environment. Each session corresponds to one environment, previously ordered according to their difficulty for the patient.
Study NCT06104176 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT in group
Description: All subjects will have 4 sessions of group CBT (one per week) during the first month following their inclusion, and then randomly assigned (ratio 1:1) to VRET group or individual CBT group. Subjects will undergo 4 additional sessions of VRET or individual CBT (one per week) during the second month.~VRET consists on 4 weekly sessions (one per week, for 1 month) of 60 to 90 minutes duration. Each session, consists in 20 to 30 minutes exposure with 10 minutes breaks (2 to 3 exposure per session). Four environments will be used: The home environment, the metro advertising environment , the party environment, and the supermarket environment. Each session corresponds to one environment, previously ordered according to their difficulty for the patient.
Study NCT06104176 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality exposure
Description: ll subjects will have 4 sessions of group CBT (one per week) during the first month following their inclusion, and then randomly assigned (ratio 1:1) to VRET group or individual CBT group. Subjects will undergo 4 additional sessions of VRET or individual CBT (one per week) during the second month.~VRET consists on 4 weekly sessions (one per week, for 1 month) of 60 to 90 minutes duration. Each session, consists in 20 to 30 minutes exposure with 10 minutes breaks (2 to 3 exposure per session). Four environments will be used: The home environment, the metro advertising environment , the party environment, and the supermarket environment. Each session corresponds to one environment, previously ordered according to their difficulty for the patient.
Study NCT06104176 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: individual CBT
Description: ll subjects will have 4 sessions of group CBT (one per week) during the first month following their inclusion, and then randomly assigned (ratio 1:1) to VRET group or individual CBT group. Subjects will undergo 4 additional sessions of VRET or individual CBT (one per week) during the second month.~VRET consists on 4 weekly sessions (one per week, for 1 month) of 60 to 90 minutes duration. Each session, consists in 20 to 30 minutes exposure with 10 minutes breaks (2 to 3 exposure per session). Four environments will be used: The home environment, the metro advertising environment , the party environment, and the supermarket environment. Each session corresponds to one environment, previously ordered according to their difficulty for the patient.
Study NCT05964608 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Therapy
Description: Structured interviews, consisting of a total of 6 sessions, were held once every two weeks for men with premature ejaculation problems. Behavioral therapy took place once every two weeks for a total of six 45-minute sessions. The stop-start technique was the therapy used. Behavioral therapy interviews were conducted at the urology outpatient clinic of the hospital. Post-tests were administered to men with premature ejaculation (PEDT) and their spouses (FSFI and SQOL-F) immediately after the 6th session was completed.
Study NCT02080429 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Passive Descent
Study NCT02080429 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pushing
Study NCT06287632 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Recruitment/ITP-CPAP (Intervention A)
Description: Participant will receive a recruitment maneuver followed by CPAP set to the level of end-expiratory esophageal pressure (measured during atmospheric pressure breathing). The intervention will last for 20 minutes.
Study NCT06287632 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard CPAP (Intervention B)
Description: Participant will receive their home CPAP (if on CPAP at home) or CPAP at 8-10 cmH20 (if not on CPAP at home or no known diagnosis of OSA). The intervention will last for 20 minutes.
Study NCT06287632 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Atmospheric Pressure
Description: Participant will breathe at atmosphere pressure (no CPAP) with supplemental oxygen as needed per clinical guidance.
Study NCT03561376 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Topical zinc oxide vs. petrolatum post-surgical scars
Description: Following linear closure on non-scalp skin with scar length > 4.5 cm, incision site will be split and petrolatum applied to one half and zinc oxide ointment to the other half daily for one month following surgery.
Study NCT06526143 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: M2VA Pain Care Pathway (M2VAPCP)
Description: M2VAPCP is a manualized Motivational Interviewing-based intervention, designed to motivate Veterans to engage in multimodal nonpharmacological pain care and reduce substance misuse when present. The first session includes empathic exploration of the Veteran's MSD, pain experiences, and motivations for pain care; psychoeducation about the benefits of multimodal pain care and judicious use of non-opioid medications; information about available pain management services and treatments for conditions that might exacerbate chronic pain; screening for substance misuse, including prescription medications, and motivational enhancement to change behaviors related to positive screens; and for those interested, making plans to achieve these goals. Over 12 weeks, case managers will hold up to two additional sessions with participants to check on their goal achievement and continue motivational enhancement for multimodal pain treatment and reduced substance misuse.
Study NCT06526143 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: M2VA Pain Care Pathway (M2VAPCP)
Description: M2VAPCP is a manualized Motivational Interviewing-based intervention, designed to motivate Veterans to engage in multimodal nonpharmacological pain care and reduce substance misuse when present. The first session includes empathic exploration of the Veteran's MSD, pain experiences, and motivations for pain care; psychoeducation about the benefits of multimodal pain care and judicious use of non-opioid medications; information about available pain management services and treatments for conditions that might exacerbate chronic pain; screening for substance misuse, including prescription medications, and motivational enhancement to change behaviors related to positive screens; and for those interested, making plans to achieve these goals. Over 12 weeks, case managers will hold up to two additional sessions with participants to check on their goal achievement and continue motivational enhancement for multimodal pain treatment and reduced substance misuse.
Study NCT06526143 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Implementation Facilitation
Description: Implementation facilitation teams consisting of internal and external facilitators will conduct activities for two purposes:~1. to build working relationships within the pain and addiction care pathways to achieve the shared goal of implementing high-quality M2VAPCP; and~2. to promote constructive, problem-solving oriented communication based on indicators of M2VAPCP implementation progress.~Activities will include Virtual Site Visits, all-side facilitation team meetings, local facilitation team meetings, M2VAPCP consultation groups, learning collaboratives, case identification reports and audit and feedback.
Study NCT05277051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK4381562
Description: GSK4381562 will be administered.
Study NCT05277051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Dostarlimab will be administered.
Study NCT05016583 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Paula Method
Description: 12 weeks of Paula Method of Exercises
Study NCT06324929 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Survey
Description: Participants complete a 35-minute survey to characterize demographics, parity, literacy, AEP risk, drinking levels, knowledge of FASD, location, Tribal affiliation, cultural preferences for tailoring, preferred digital platforms, methods of access to mobile devices/Internet, and interest in a digital women's health study about alcohol and birth control.
Study NCT04983563 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Actigraphy, eTact
Description: Actigraphy will be realized twice a day during 30 minutes and Lipsitz scoring system will be realized at the same moment to analyze the correlation between Lipsitz scoring system and actigraphy.
Study NCT05277051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belrestotug
Description: Belrestotug will be administered.
Study NCT05277051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nelistotug
Description: Nelistotug will be administered.
Study NCT05277051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK5764227
Description: GSK5764227 will be administered.
Study NCT06523075 — intervention group
Intervention type: OTHER
Intervention: Tumor Necrosis Factor
Description: This study is a retrospective observational study, with Tumor Necrosis Factor being one of the exposure factors under investigation.
Study NCT06523075 — intervention group
Intervention type: OTHER
Intervention: Interleukin-1β
Description: This study is a retrospective observational study, with Interleukin-1β being one of the exposure factors under investigation.
Study NCT06523075 — intervention group
Intervention type: OTHER
Intervention: Interleukin-12
Description: This study is a retrospective observational study, with Interleukin-12 being one of the exposure factors under investigation.
Study NCT06523075 — intervention group
Intervention type: OTHER
Intervention: Interleukin-18
Description: This study is a retrospective observational study, with Interleukin-18 being one of the exposure factors under investigation.
Study NCT06523075 — intervention group
Intervention type: OTHER
Intervention: Complement C3
Description: This study is a retrospective observational study, with Complement C3 being one of the exposure factors under investigation.
Study NCT05644041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine will be administered intravesically at a dose of 2000 mg.
Study NCT04834310 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cefazolin
Description: All patients will receive an intraoperative dose of IV Cefazolin 2 g (re-dose after 4 hours) or IV Clindamycin 600mg (re-dose after 6 hours) for penicillin allergic patients.
Study NCT04834310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefazolin
Description: All patients will receive an intraoperative dose of IV Cefazolin 2 g (re-dose after 4 hours) or IV Clindamycin 600mg (re-dose after 6 hours) for penicillin allergic patients.
Study NCT04834310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cephalexin
Description: The experimental group will receive a postoperative 5-day course of Cephalexin 500 mg QID or Clindamycin 300 mg QID for penicillin allergic patients. All capsules will be encapsulated with size 00 dark-colored capsules compounded by the UCLA Investigational Pharmacy.
Study NCT04834310 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo group will receive a postoperative 5-day course of placebos (sugar capsules). All capsules will be encapsulated with size 00 dark-colored capsules compounded by the UCLA Investigational Pharmacy.
Study NCT05217238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Advanced intravenous injection of remifentanil before the rocuronium injection
Study NCT06523075 — intervention group
Intervention type: OTHER
Intervention: Complement C5
Description: This study is a retrospective observational study, with Complement C5 being one of the exposure factors under investigation.
Study NCT05277675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab/Sintilimab+Lenvatinib/Bevacizumab
Description: Immune checkpoint inhibitor (tislelizumab/sintilimab) combined with anti-angiogenic drugs (lenvatinib/bevacizumab) used as neoadjuvant therapy
Study NCT05277675 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RFA
Description: RFA will be performed in a percutaneous way guided contrast enhanced ultrasound.
Study NCT05277675 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RFA
Description: RFA will be performed in a percutaneous way guided contrast enhanced ultrasound.
Study NCT05908032 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM310
Description: IL-4Rα monoclonal antibody